India, July 20 -- Nuvation Bio Inc. (NUVB), an oncology company, announced Monday updated positive long-term follow-up data from the Phase 2 J201 study evaluating safusidenib in chemotherapy- and radiotherapy-naive patients with grade 2 IDH1-mutant glioma.
The company also announced two expansion studies to evaluate safusidenib across the broader IDH1-mutant glioma landscape.
Gliomas are the most common adult brain tumours. According to the company's estimate, in the U.S., about 2,500 patients are diagnosed annually with IDH-mutant gliomas, over 95% of which carry an IDH1 mutation. Notably, the disease remains incurable despite relatively longer survival in patients with IDH1-mutant tumours.
Safusidenib is an investigational oral, brain-...